Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes – an update

Bibliography

• Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26(3):832-6
   PubMed Web of Science ®Google Scholar
• White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009;373(9677):1808-17
   PubMed Web of Science ®Google Scholar
• Bretzel RG, Jahr H, Eckhard M, Islet cell transplantation today. Langenbecks Arch Surg 2007;392(3):239-53
   PubMed Web of Science ®Google Scholar
• Ryan EA, Paty BW, Senior PA, Five-year follow-up after clinical islet transplantation. Diabetes 2005;54(7):2060-9
   PubMed Web of Science ®Google Scholar
• Achenbach P, Bonifacio E, Ziegler AG. Predicting type 1 diabetes. Curr Diab Rep 2005;5(2):98-103
   PubMedGoogle Scholar
• Bougneres PF, Landais P, Boisson C, Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990;39(10):1264-72
   PubMed Web of Science ®Google Scholar
• Cohen IR. Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 2002;45(10):1468-74
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 2005;28(5):1068-76
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359(18):1909-20
   PubMed Web of Science ®Google Scholar
• Solvason N, Lou YP, Peters W, Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008;181:8298-30711
   PubMed Web of Science ®Google Scholar
• Gottlieb P, Eisenbarth G, Kipnes M, T. 114 Interim results of a Phase I/II clinical trial of a DNA Plasmid Vaccine (BHT –3021) for type 1 diabetes, clinical immunology. Volume 131, Supplement 1. FOCIS 2009 Abstract Supplement – 9th Annual Meeting, Federation of Clinical Immunology Societies; 2009. p. S84
   Google Scholar
• Herold KC, Hagopian W, Auger JA, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-8
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9(9):1202-8
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352(25):2598-608
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996;39(9):1005-29
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356(15):1517-26
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-53
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Cohen IR. Regulatory T cells and immune computation. Eur J Immunol 2008;38(4):903-7
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Tal G, Shivtiel S, Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis, and inflammation. J Immunol 2005;175(1):276-85
   PubMed Web of Science ®Google Scholar
• Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann NY Acad Sci 2001;928:200-11
   PubMed Web of Science ®Google Scholar
• Abulafia-Lapid R, Elias D, Raz I, T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999;12(2):121-9
   PubMed Web of Science ®Google Scholar
• Elias D, Reshef T, Birk OS, Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991;88(8):3088-91
   PubMed Web of Science ®Google Scholar
• Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994;343(8899):704-6
   PubMed Web of Science ®Google Scholar
• Elias D, Cohen IR. The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Diabetes 1996;45(9):1168-72
   PubMed Web of Science ®Google Scholar
• Elias D, Cohen IR. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 1995;44(9):1132-8
   PubMed Web of Science ®Google Scholar
• Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998;11(1):73-81
   PubMed Web of Science ®Google Scholar
• Elias D, Meilin A, Ablamunits V, Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997;46(5):758-64
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Carmi P, Cohen IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. J Immunol 2002;169(10):6030-5
   PubMed Web of Science ®Google Scholar
• Huurman VA, Decochez K, Mathieu C, Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007;23(4):269-75
   PubMed Web of Science ®Google Scholar
• Huurman VA, van der Meide PE, Duinkerken G, Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008;152(3):488-97
   PubMed Web of Science ®Google Scholar
• Raz I, Avron A, Tamir M, Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, Phase II trial. Diabetes Metab Res Rev 2007;23(4):292-8
   PubMed Web of Science ®Google Scholar
• Elias D, Avron A, Tamir M, Raz I. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann NY Acad Sci 2006;1079:340-4
   PubMed Web of Science ®Google Scholar
• Schloot NC, Meierhoff G, Lengyel C, Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23(4):276-85
   PubMed Web of Science ®Google Scholar
• Lazar L, Ofan R, Weintrob N, Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23(4):286-91
   PubMed Web of Science ®Google Scholar
• Roep BO, Atkinson M. Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 2004;47(10):1650-6
   PubMed Web of Science ®Google Scholar
• Wallensteen M, Dahlquist G, Persson B, Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988;31(9):664-9
   PubMed Web of Science ®Google Scholar
• Jin L, Zhu A, Wang Y, A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol 2008;180(1):58-63
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342(6):381-389
   PubMed Web of Science ®Google Scholar
• Waldron-Lynch F, von Herrath M, Herold KC. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Found Symp 2008;292:146-55; discussion 55-8, 202-3
   PubMedGoogle Scholar